Published in Gene Therapy Weekly, September 9th, 1996
The immunization protocol apparently is suitable for human testing.
"This should be well tolerated in humans," said William M. Mitchell of Vanderbilt University, Nashville, Tennessee. "This is an active biologic metabolite of vitamin D3. It is currently used in clinical medicine and is an FDA-approved drug."
Mitchell described the mouse studies in a presentation to the XI International Conference on AIDS, held July 7-12, 1996, in Vancouver, British Columbia, Canada.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly